F11 and ischemic stroke: The efficacy results of ongoing phase III studies will be necessary to better define the role of FXI inhibitors, which could represent a further therapeutic option not only for the prevention of ischemic stroke, redefining the relationship between efficacy and safety in these critical clinical scenarios.